Stefan Rehnmark
Chief Tech/Sci/R&D Officer at GABATHER AB
Profile
Stefan Rehnmark is the founder of Axcentua Pharmaceuticals AB, which was founded in 2007.
He held the title of Chief Executive & Scientific Officer at the company.
Dr. Rehnmark is also the founder of Noviga Research AB.
He is currently the Chief Scientific Officer at Gabather AB.
Dr. Rehnmark previously worked as an Assistant Professor at the University of Stockholm from 1994 to 2000.
He obtained a doctorate degree from the University of Stockholm.
Stefan Rehnmark active positions
Companies | Position | Start |
---|---|---|
GABATHER AB | Chief Tech/Sci/R&D Officer | 2017-12-31 |
Former positions of Stefan Rehnmark
Companies | Position | End |
---|---|---|
University of Stockholm | Corporate Officer/Principal | 1997-12-31 |
Noviga Research AB | Founder | - |
Axcentua Pharmaceuticals AB
Axcentua Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology Axcentua Pharmaceuticals AB develops anti-cancer drugs for pancreatic cancer patients. It generates investigational new drugs for diseases with unmet medical need in Sweden. The firm offers AXP107-11, multi-targeted chemosensitizer and a small-molecule anti-cancer compound for the treatment of various solid tumors, such as non-small cell lung cancers. The company was founded in 2007 by Anders Berkenstam, Stefan Rehnmark and Michael-Robin Witt and is headquartered in Stockholm, Sweden. | Chief Executive Officer | - |
Training of Stefan Rehnmark
University of Stockholm | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 1 |
---|---|
GABATHER AB | Health Technology |
Private companies | 2 |
---|---|
Axcentua Pharmaceuticals AB
Axcentua Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology Axcentua Pharmaceuticals AB develops anti-cancer drugs for pancreatic cancer patients. It generates investigational new drugs for diseases with unmet medical need in Sweden. The firm offers AXP107-11, multi-targeted chemosensitizer and a small-molecule anti-cancer compound for the treatment of various solid tumors, such as non-small cell lung cancers. The company was founded in 2007 by Anders Berkenstam, Stefan Rehnmark and Michael-Robin Witt and is headquartered in Stockholm, Sweden. | Health Technology |
Noviga Research AB |
- Stock Market
- Insiders
- Stefan Rehnmark